Bevacizumab offers no benefit for newly diagnosed glioblastoma, MD Anderson-led study finds
The angiogenesis inhibitor bevacizumab (Avastin) failed to increase
overall survival (OS) or statistically significant progression-free
survival (PFS) for glioblastoma patients in the frontline setting,
according to research led by researchers at The University of Texas MD
Anderson Cancer Center.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news